Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938404 · ClinicalTrials.gov registry record
Octaplas Adult TTP Trial
A clinical trial, sponsored by Octapharma.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01938404: Clinical Trial study, sponsored by Octapharma.
NCT01938404 is a clinical trial that was terminated before completion, run by Octapharma. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01938404 was terminated before completion, sponsored by Octapharma.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).
Interventions
- BIOLOGICAL Octaplas
- DRUG Standard Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2017-08-02 |
Why NCT01938404 stopped before completion
NCT01938404 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Octaplas is the first listed.
NCT01938404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01938404 about?
NCT01938404 is a clinical study titled "Octaplas Adult TTP Trial". To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on th...
What is the current status of trial NCT01938404?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2017-06-06. Estimated completion is 2017-08-02.
What interventions are being tested in trial NCT01938404?
The interventions under investigation include: Octaplas (BIOLOGICAL), Standard Plasma (DRUG).
Who is sponsoring clinical trial NCT01938404?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI